4.7 Article

Evolutionarily Conserved Signaling Pathways: Acting in the Shadows of Acute Myelogenous Leukemia's Genetic Diversity

期刊

CLINICAL CANCER RESEARCH
卷 21, 期 2, 页码 240-248

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-14-1436

关键词

-

类别

资金

  1. German Research Council (DFG)

向作者/读者索取更多资源

Acute myelogenous leukemia stem cells (AML-LSC) give rise to the leukemic bulk population and maintain disease. Relapse can arise from residual LSCs that have distinct sensitivity and dependencies when compared with the AML bulk. AML-LSCs are driven by genetic and epigenomic changes, and these alterations influence prognosis and clonal selection. Therapies targeting these molecular aberrations have been developed and show promising responses in advanced clinical trials; however, so far success with LSCs has been limited. Besides the genetic diversity, AML-LSCs are critically influenced by the microenvironment, and a third crucial aspect has recently come to the fore: A group of evolutionarily conserved signaling pathways such as canonical Wnt signaling, Notch signaling, or the Hedgehog pathway can be essential for maintenance of AML-LSC but may be redundant for normal hematopoietic stem cells. In addition, early reports suggest also regulators of cell polarity may also influence hematopoietic stem cells and AML biology. Interactions between these pathways have been investigated recently and suggest a network of signaling pathways involved in regulation of self-renewal and response to oncogenic stress. Here, we review how recent discoveries on regulation of AML-LSC-relevant evolutionarily conserved pathways may open opportunities for novel treatment approaches eradicating residual disease. (C) 2015 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Combined Activity of the Redox-Modulating Compound Setanaxib (GKT137831) with Cytotoxic Agents in the Killing of Acute Myeloid Leukemia Cells

Muhammed Burak Demircan, Peter C. Mgbecheta, Anne Kresinsky, Tina M. Schnoeder, Katrin Schroeder, Florian H. Heidel, Frank D. Boehmer

Summary: AML cells have high levels of ROS, which promote cell proliferation and oxidative stress. Setanaxib, a compound that inhibits NOX4 and modulates ROS, showed inhibitory activity on AML cells and enhanced the cytotoxic effect of anthracyclines.

ANTIOXIDANTS (2022)

Letter Hematology

Rhabdomyolysis induced by nelarabine

Christian Spaeth, Mandy Schoenau, Sophie Gaubert, Thomas Neumann, Christian A. Schmidt, Florian H. Heidel, William H. Krueger

ANNALS OF HEMATOLOGY (2022)

Article Multidisciplinary Sciences

Taz protects hematopoietic stem cells from an aging-dependent decrease in PU.1 activity

Kyung Mok Kim, Anna Mura-Meszaros, Marie Tollot, Murali Shyam Krishnan, Marco Grundl, Laura Neubert, Marco Groth, Alejo Rodriguez-Fraticelli, Arthur Flohr Svendsen, Stefano Campaner, Nico Andreas, Thomas Kamradt, Steve Hoffmann, Fernando D. Camargo, Florian H. Heidel, Leonid Bystrykh, Gerald de Haan, Bjorn von Eyss

Summary: As individuals age, the immune system's function declines due to defects in hematopoietic stem cells (HSCs). Researchers have discovered that the Hippo pathway coactivator TAZ plays a crucial role in protecting aging HSCs from functional decline by buffering the loss of PU.1 activity, and have identified Clca3a1 as a marker for young-like HSCs even in old mice.

NATURE COMMUNICATIONS (2022)

Article Hematology

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

Steffen Koschmieder, Susanne Isfort, Dominik Wolf, Florian H. Heidel, Andreas Hochhaus, Philippe Schafhausen, Martin Griesshammer, Denise Wolleschak, Uwe Platzbecker, Konstanze Doehner, Philipp J. Jost, Stefani Parmentier, Markus Schaich, Nikolas von Bubnoff, Frank Stegelmann, Angela Maurer, Martina Crysandt, Deniz Gezer, Maike Kortmann, Jeremy Franklin, Julia Frank, Martin Hellmich, Tim H. Bruemmendorf

Summary: This study found that treatment with ruxolitinib is effective, well-tolerated, and efficient for previously untreated patients with polycythemia vera, with significant reduction in symptoms and improvement in hematological parameters.

ANNALS OF HEMATOLOGY (2023)

Article Hematology

Dynamic DNA methylation reveals novel cis-regulatory elements in mouse hematopoiesis

Maximilian Schoenung, Mark Hartmann, Stephen Kraemer, Sina Staeble, Mariam Hakobyan, Emely Kleinert, Theo Aurich, Defne Cobanoglu, Florian H. Heidel, Stefan Froehling, Michael D. Milsom, Matthias Schlesner, Pavlo Lutsik, Daniel B. Lipka

Summary: The study reveals significant changes in DNA methylation during the differentiation of hematopoietic cells, which is associated with the differentiation of immune cells. By using the Infinium Mouse Methylation BeadChip technology, researchers successfully obtained a detailed DNA methylation map of mouse hematopoiesis. They found that dynamically regulated DNA methylation is closely associated with cell type-specificity and the expression of hematopoietic genes, and identified a large number of novel putative cis-regulatory elements. This study provides an important platform for studying the epigenetic regulation of normal and malignant hematopoiesis.

EXPERIMENTAL HEMATOLOGY (2023)

Article Oncology

Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia

Jasmin Straube, Theresa Eifert, Therese Vu, Yashaswini Janardhanan, Rohit Haldar, Bjoern von Eyss, Leanne Cooper, Claudia Bruedigam, Victoria Y. Ling, Emily Cooper, Ann-Marie Patch, Lars Bullinger, Tina M. Schnoeder, Megan Bywater, Florian H. Heidel, Steven W. Lane

Summary: Murine models are useful for studying AML subtypes and compound mutations. The Cre recombinase expression in a transgenic murine model can lead to aggressive leukemia phenotype, polyclonal expansion of FLT3(ITD/ITD) progenitor cells, differentiation block and activation of Myc-dependent gene expression programs. Our report highlights the potential risks and unexpected effects of Cre expression in investigating oncogenic mutations in murine cancer models.

LEUKEMIA (2023)

Review Oncology

Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany

Andreas Schmidt, Christiane Bernhardt, Dieter Buerkle, Stefan Fries, Carla V. Hannig, Kathleen Jentsch-Ullrich, Andreas Josting, Stephan Kreher, Marcel Reiser, Hans Tilman Steinmetz, Hans Tesch, Stephanie Terner, Alexander Schulte, Carl C. Crodel, Francesca Palandri, Florian H. Heidel

Summary: This study evaluated the real-life approach to clinical characteristics, diagnostic assessment, risk stratification, and treatment decisions for MPN patients classified as ET or MF after the implementation of the WHO 2016 classification. It was found that some patients diagnosed with ET did not undergo bone marrow testing, and some patients diagnosed with MF did not receive early prognostic risk assessment. Improved histopathologic diagnostics and dynamic risk stratification are recommended for precise risk assessment and therapeutic stratification.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Article Oncology

Pomalidomide combinations are a safe and effective option after daratumumab failure

Annamaria Brioli, Laura Gengenbach, Katia Mancuso, Mascha Binder, Thomas Ernst, Florian H. Heidel, Thomas Stauch, Elena Zamagni, Inken Hilgendorf, Andreas Hochhaus, Monika Engelhardt, Marie von Lilienfeld-Toal

Summary: This study investigates the role of pomalidomide combinations in daratumumab-refractory multiple myeloma (MM) patients. The results show that pomalidomide-based combinations can be effective and safe for daratumumab-refractory patients.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Letter Oncology

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)

Frank Stegelmann, Lino L. Teichmann, Florian H. Heidel, Carl C. Crodel, Thomas Ernst, Sebastian Kreil, Andreas Reiter, Sara Otten, Stefanie Schauer, Ruth-Miriam Korber, Kim Kricheldorf, Susanne Isfort, Hartmut Doehner, Tim H. H. Bruemmendorf, Martin Griesshammer, Konstanze Doehner, Steffen Koschmieder

LEUKEMIA (2023)

Article Oncology

Primary myelofibrosis Diagnosis, clinical presentation and treatment options

Florian H. Heidel, Carl C. Crodel, Hans H. Kreipe

Summary: This review focuses on primary myelofibrosis (PMF) and provides an overview of diagnostic criteria, clinical presentation, and therapeutic options. Diagnostic criteria include histopathologic characteristics, molecular evidence, and exclusion of other myeloid neoplasms. Treatment strategies are based on risk of progression and symptom burden, including allogeneic stem cell transplantation and JAK inhibitors.

ONKOLOGIE (2023)

暂无数据